Advantages and disadvantages of using Rho kinase inhibitors to reduce intraocular pressure

References

• Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113–1124. doi: 10.1056/NEJMra0804630
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040 a systematic review and meta-analysis. Ophthalmol. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013
   PubMed Web of Science ®Google Scholar
• Berryman JD, Novack GD. Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Expert Rev Ophthalmol. 2019;14(4–5):1–7. doi: 10.1080/17469899.2019.1645008
   Web of Science ®Google Scholar
• Singh K, Singh A. Rho-kinase inhibitors in ocular diseases: a translational research journey. J Curr Glaucoma Pract. 2023;17(1):44–48. doi: 10.5005/jp-journals-10078-1396
   PubMedGoogle Scholar
• Clement Freiberg J, von Spreckelsen A, Kolko M, et al. Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022;6(6). doi: 10.1002/14651858.CD013817.pub2
   PubMedGoogle Scholar
• Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol. 2008;295(5):C1057–1070. doi: 10.1152/ajpcell.00481.2007
   PubMed Web of Science ®Google Scholar
• Rao VP, Epstein DL. Rho GTPase/rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21(3):167–177. doi: 10.2165/00063030-200721030-00004
   PubMed Web of Science ®Google Scholar
• Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2017;158:23–32. doi: 10.1016/j.exer.2016.08.023
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51. doi: 10.1089/jop.2017.0023
   PubMed Web of Science ®Google Scholar
• Ren R, Li G, Le TD, et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–6209. doi: 10.1167/iovs.16-20189
   PubMed Web of Science ®Google Scholar
• Sturdivant JM, Royalty SM, Lin CW, et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. 2016;26(10):2475–2480. doi: 10.1016/j.bmcl.2016.03.104
   PubMed Web of Science ®Google Scholar
• Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39(8):813–822. doi: 10.3109/02713683.2013.874444
   PubMed Web of Science ®Google Scholar
• Isobe T, Ohta M, Kaneko Y, et al. Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase. Xenobiotica. 2016;46(7):579–590. doi: 10.3109/00498254.2015.1096981
   PubMed Web of Science ®Google Scholar
• Hartman PJ, Cooke DL, Hsu HH, et al. Phase I/II, double-masked, randomized, vehicle-controlled study of H-1337 ophthalmic solution for glaucoma and ocular hypertension. Ophthalmol Glaucoma. 2023;6(2):198–205. doi: 10.1016/j.ogla.2022.08.015
   PubMedGoogle Scholar
• Li Y, Yao L, Dang K, et al. Discovery and preclinical development of VN539, a novel ROCK and NO dual MOA agent for the treatment of glaucoma in normotensive rabbits model with minimal hyperemia. Invest Ophthalmol Visual Sci. 2022;63(7):150–A0343.
   Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho Kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127. doi: 10.1016/j.ajo.2017.11.019
   PubMed Web of Science ®Google Scholar
• Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104. doi: 10.1016/j.ajo.2019.03.002
   PubMed Web of Science ®Google Scholar
• Kazemi A, McLaren JW, Kopczynski CC, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380–386. doi: 10.1089/jop.2017.0138
   PubMed Web of Science ®Google Scholar
• Sit AJ, Gupta D, Kazemi A, et al. Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study. Am J Ophthalmol. 2021;226:262–269. doi: 10.1016/j.ajo.2021.01.019
   PubMed Web of Science ®Google Scholar
• Araie M, Sugiyama K, Aso K, et al. Phase 2 randomized clinical study of netarsudil ophthalmic solution in Japanese patients with primary open-angle glaucoma or ocular hypertension. Adv Ther. 2021;38(4):1757–1775. doi: 10.1007/s12325-021-01634-9
   PubMed Web of Science ®Google Scholar
• Zaman F, Gieser SC, Schwartz GF, et al. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021;37(6):1011–1020. doi: 10.1080/03007995.2021.1901222
   PubMed Web of Science ®Google Scholar
• Araie M, Sugiyama K, Aso K, et al. Phase 3 clinical trial comparing the safety and efficacy of netarsudil to ripasudil in patients with primary open-angle glaucoma or ocular hypertension: Japan rho kinase elevated intraocular pressure treatment trial (J-ROCKET). Adv Ther. 2023;40(10):4639–4656. doi: 10.1007/s12325-023-02550-w
   PubMed Web of Science ®Google Scholar
• Wang B, Zimmermann CM, Kraus CL. Netarsudil in the management of refractory pediatric glaucoma. J AAPOS. 2023;27(5):296–298. doi: 10.1016/j.jaapos.2023.06.008
   PubMed Web of Science ®Google Scholar
• Mathur MC, Ratnam PV, Saikumar SJ, et al. Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: a real-world evaluation of efficacy and safety. Indian J Ophthalmol. 2023;71(6):2500–2503. doi: 10.4103/IJO.IJO_25_23
   PubMed Web of Science ®Google Scholar
• Kaufman AR, Elhusseiny AM, Edward DP, et al. Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: a pilot investigation in Sturge-weber syndrome. Eur J Ophthalmol. 2023;33(5):1969–1976. doi: 10.1177/11206721231159694
   PubMed Web of Science ®Google Scholar
• Samuel S, El Helwe H, Neeson CE, et al. Netarsudil as an adjunctive therapy: efficacy and factors contributing to a favorable IOP-Lowering effect. J Ophthalmol. 2022;2022:1–15. doi: 10.1155/2022/6925027
   Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–736.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Kakuda T, Sano T, et al. Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months. Adv Ther. 2022;39(4):1659–1677. doi: 10.1007/s12325-021-02023-y
   PubMed Web of Science ®Google Scholar
• Tsukahara S, Enomoto N, Ishida K, et al. One-year efficacy and safety assessment of ripasudil, a Rho kinase inhibitor, in an addition to or replacing existing treatment regimens: a retrospective study. J Ocul Pharmacol Ther. 2020;36(7):512–521. doi: 10.1089/jop.2019.0089
   PubMed Web of Science ®Google Scholar
• Oydanich M, Roll EH, Uppuluri S, et al. Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma. Can J Ophthalmol. 2023. doi: 10.1016/j.jcjo.2023.05.009
   PubMedGoogle Scholar
• Lin MM, Moster SJ, Zheng CX, et al. Netarsudil’s effect in eyes with a history of selective laser trabeculoplasty. Ophthalmol Glaucoma. 2020;3(4):306–308. doi: 10.1016/j.ogla.2020.01.005
   PubMedGoogle Scholar
• Kusuhara S, Katsuyama A, Matsumiya W, et al. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):809–814. doi: 10.1007/s00417-018-3933-9
   PubMed Web of Science ®Google Scholar
• Futakuchi A, Morimoto T, Ikeda Y, et al. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Sci Rep. 2020;10(1):10308. doi: 10.1038/s41598-020-66928-4
   PubMed Web of Science ®Google Scholar
• Yanai R, Uchi SH, Kobayashi M, et al. Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid. Int J Ophthalmol. 2023;16(6):904–908. doi: 10.18240/ijo.2023.06.11
   PubMed Web of Science ®Google Scholar
• Wirta D, Li X-Y, Shen W, et al. Phase 2 study of the ocular hypotensive activity and safety of VVN539 ophthalmic solution. Ophthalmol Sci. 2023;4(2):100426. doi: 10.1016/j.xops.2023.100426
   PubMedGoogle Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. discussion 829-730. doi: 10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Osterberg L, Vrijens B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Ann Rev Pharm Toxicol. 2011;52(1):275–301. doi: 10.1146/annurev-pharmtox-011711-113247
   PubMedGoogle Scholar
• Brubaker RF. Goldmann’s equation and clinical measures of aqueous dynamics. Exp Eye Res. 2004;78(3):633–637. doi: 10.1016/j.exer.2003.07.002
   PubMed Web of Science ®Google Scholar
• Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF 2α on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6(8):1035–1044. doi: 10.3109/02713688709034874
   PubMed Web of Science ®Google Scholar
• Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280–289. doi: 10.1016/j.ogla.2019.03.007
   PubMedGoogle Scholar
• Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620–1631. doi: 10.1007/s12325-020-01277-2
   PubMed Web of Science ®Google Scholar
• Stalmans I, Lim KS, Oddone F, et al. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2023;262(1):179–190. doi: 10.1007/s00417-023-06192-0
   PubMed Web of Science ®Google Scholar
• Pham AT, Bradley C, Casey C, et al. Effectiveness of netarsudil versus Brimonidine in eyes already being treated with glaucoma medications at a single academic tertiary care practice: a comparative study. Curr Ther Res Clin Exp. 2023;98:100689. doi: 10.1016/j.curtheres.2022.100689
   PubMed Web of Science ®Google Scholar
• Tanihara H, Yamamoto T, Aihara M, et al. Crossover randomized study of pharmacologic effects of ripasudil-brimonidine fixed-dose combination versus ripasudil or brimonidine. Adv Ther. 2023;40(8):3559–3573. doi: 10.1007/s12325-023-02534-w
   PubMed Web of Science ®Google Scholar
• Tanihara H, Yamamoto T, Aihara M, et al. Ripasudil-brimonidine fixed-dose combination vs ripasudil or brimonidine: two phase 3 randomized clinical trials. Am J Ophthalmol. 2023;248:35–44. doi: 10.1016/j.ajo.2022.11.017
   PubMed Web of Science ®Google Scholar
• Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose-response study of AR-13324 vs. latanoprost in patients with elevated intraocular pressure. Ophthalmol. 2015;122(2):302–307. doi: 10.1016/j.ophtha.2014.08.022
   PubMed Web of Science ®Google Scholar
• Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution. Am J Ophthalmol. 2019;200:130–137. doi: 10.1016/j.ajo.2019.01.003
   PubMed Web of Science ®Google Scholar
• Saito H, Kagami S, Mishima K, et al. Long term side effects including blepharitis leading to discontinuation of Ripasudil. J Glaucoma. 2019;28(4):289–293. doi: 10.1097/IJG.0000000000001203
   PubMed Web of Science ®Google Scholar
• Davanian AM. Netarsudil-associated reticular bullous epithelial edema. Eyenet. 2023;27(6):58–58.
   Google Scholar
• Chang EL, Emmel DK, Teng CC, et al. Anterior subcapsular cataract formation with long-term topical netarsudil treatment for glaucoma. J Glaucoma. 2022;31(1):60–63. doi:10.1097/IJG.0000000000001956
   PubMed Web of Science ®Google Scholar
• Tanna AP, Esfandiari H, Teramoto K. Reversible corneal endothelial abnormalities with Netarsudil. J Glaucoma. 2020;29(6):e41–e43. doi: 10.1097/IJG.0000000000001507
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Komatsu K, Tokumo K, et al. A multicenter phase II study on the safety of rho-kinase inhibitor (ripasudil) with needling for the patients after trabeculectomy. Contemp Clin Trials Commun. 2023;33:101160. doi: 10.1016/j.conctc.2023.101160
   PubMed Web of Science ®Google Scholar